Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2002

View Archived Issues

Wyeth patents novel antiatherosclerotic agents

New analgesics in the Gruenenthal pipeline

Carbapenem antibiotics presented by Banyu

Toa Eiyo claims chymase inhibitors for use in hypertension and other disorders

Cell adhesion inhibitors and their use in asthma, inflammation, etc.

Nikken Chemicals patents TNF-alpha production inhibitors

Quinolines and isoquinolines identified as factor Xa inhibitors

Endostatin enters phase II trial in stage IV metastatic melanoma

Wilex and Aventis sponsor phase III trial in high-risk breast cancer

Preliminary data from human studies on gimatecan reported in Orlando

Opioid treatment of IBS associated with constipation provides symptom relief

ASCO presentation reports preliminary PK data and good tolerance for ILX-651

Dolastatin 10 assessed in phase II trial in advanced renal cell carcinoma at Mayo Clinic

Two different schedules of administration for AG-2037 under study in cancer patients

Preclinical and clinical results presented at major cancer meeting for SAHA, an HDAC inhibitor

Spotlight on topoisomerase inhibitors under development

AnorMED reviews fiscal 2002 and anticipates 2003 milestones

NP-1 enters phase II trials in neuropathic pain

Arena and Ferring collaborate on drug discovery in reproductive health

Novirio changes name to Idenix

NV-04 moves into clinical testing in cardiovascular disease

SIGA Technologies awarded SBIR grant for antibiotic development

IND filed for MDX-060

Genelabs expects Aslera NDA response by August 2002

Oncophage granted orphan drug status in renal cell carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...